The Rottendorf Foundation transforms income from the “Rottendorf Pharma” company into added social value in accordance with the statutory requirements of the founders Andreas Josef (died 1971) and Rose Rottendorf (died 1981).
As the two founders had no children of their own, they transferred their life’s work, the “Rottendorf Pharma” company, to the Rottendorf Foundation by means of a testamentary disposition. With the foundation structure they created, they associated the expectation of permanently securing and continuing the company at the Ennigerloh site in the eastern Münsterland region and of preserving the jobs there of currently more than 1,100 employees. To secure the future of the company, the foundation reinvests more than half of its earnings in the company each year.
For more information, see Rottendorf Pharma.
The Rottendorf-Foundation supports
- spirituality & philanthropy
- health care
- research into and cultivation of the Low German language
- scientific research
Part of the company’s income flows into the foundation’s diverse ecclesiastical and charitable projects. The Rottendorf Foundation is committed to the purposes specified by the two founders in the areas of ecclesiastical and charitable purposes, pharmacology and pharmacy, research into and cultivation of the Low German language, and promotion of scientific research. For more information, see the foundation’s purpose.
The Rottendorf Foundation was established in 1974 as a legally capable, charitable foundation under civil law by order of the Ministry of the Interior of the State of North Rhine-Westphalia on December 5, 1974. The foundation’s assets consist mainly of the shares in Rottendorf GmbH based in Berlin. This company holds a 100 percent stake in Rottendorf Pharma GmbH, based in Ennigerloh, Westphalia. Since July 1, 2021, the Rottendorf Foundation has been the sole shareholder of Rottendorf GmbH.